{"id":2532,"date":"2017-09-29T00:00:00","date_gmt":"2017-09-28T22:00:00","guid":{"rendered":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/"},"modified":"2019-01-13T16:38:30","modified_gmt":"2019-01-13T15:38:30","slug":"29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman","status":"publish","type":"post","link":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/","title":{"rendered":"NOXXON Supervisory Board elects experienced US &#038; EU Biotech Veteran Don deBethizy Chairman"},"content":{"rendered":"<p><strong>Previous Chairman Hubert Birner to Remain on Board, Olivier Litzka to Step Down<\/strong><\/p>\n<p><strong>Berlin, Germany, September 29, 2017<\/strong> &#8211; NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), today announced changes to its Supervisory Board. Current Board member Don deBethizy, Ph.D., has been elected new Chairman of the Supervisory Board; former Chairman Hubert Birner, Ph.D., will remain a member of the Board; and current Board member Olivier Litzka, Ph.D., will step down from the Board with effect as of the end of September 30, 2017.<\/p>\n<p>Dr. deBethizy joined the NOXXON Board in 2014, providing more than 30 years of leadership experience in the biotech and pharma industry having served as CEO, Chairman and Board member for various public and private companies both in the US and EU. Dr. Birner, Managing Partner at TVM Capital and noted international entrepreneur, joined the NOXXON Board in June 2015 and had been Chairman of the Board since July 2015. Dr. Litzka, partner with Paris-based Edmond de Rothschild Investment Partners and experienced venture capitalist, had been a Board member since 2007.<\/p>\n<p>\u201cNOXXON enjoys the support of an outstanding and deeply supportive Supervisory Board and we welcome Don into the Chairman position,\u201d said Aram Mangasarian, Ph.D., CEO of NOXXON. \u201cWe benefited tremendously from Hubert\u2019s guidance as Chairman and I am very pleased that he remains on the Board to support this next phase of NOXXON\u2019s development. I want also to extend a great deal of thanks to Olivier for his tireless commitment to the company over the years.\u201d<\/p>\n<p>\u201cNOXXON has reached a very exciting juncture with the development of its lead program NOX-A12 and the ongoing clinical program that seeks to enable greater therapeutic impact for treating pancreatic and colorectal cancer patients,\u201d said Don deBethizy, Ph.D., NOXXON\u2019s new Chairman of the Board. \u201cI look forward to continuing to work with Aram, his team and the Board to transform NOXXON into an exciting immune-therapy company and to realize the full potential of this unique technology alone and in high profile industry partnerships.\u201d<\/p>\n<p>Dr. deBethizy joined NOXXON\u2019s Board of Directors in November 2014 as an independent member. He is currently President of White City Consulting ApS in Denmark and serves on the supervisory Boards of arGEN-X NV (Euronext Brussels\/NASDAQ), Newron Pharmaceuticals S.P.A. (SIX Swiss Exchange), Proterris and Albumedix. He also served as Chairman of the Board of immuno-oncology company Rigontec GmbH until its acquisition by MSD in September 2017 and Board member of Serendex Pharmaceuticals A\/S (Oslo Stock Exchange) until its acquisition by Savara Pharmaceuticals. Dr. deBethizy has been involved in the formation, management and financing of several successful companies both in the US and the EU. He was President and CEO of Santaris Pharma A\/S until the company was sold to Roche and Executive Chairman of Contera Pharma ApS until it was sold to Bukwang Pharma in November 2014. He was also co-founder and CEO of Targacept, Inc., a public US biotechnology company listed on NASDAQ. Dr. deBethizy holds a MS and Ph.D. in toxicology from Utah State University and is a Diplomat of the American Board of Toxicology.<\/p>\n<p>Note that all above-mentioned Supervisory Board affiliations that relate to a date before September 2016 refer to NOXXON Pharma AG prior to the Corporate Reorganization described in greater detail in the Information Document dated September 27, 2016 and the Prospectus dated July 10, 2017.<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-2532\" data-postid=\"2532\" class=\"themify_builder_content themify_builder_content-2532 themify_builder tf_clear\">\n    <\/div>\n<!--\/themify_builder_content-->","protected":false},"excerpt":{"rendered":"<p>NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors<\/p>\n","protected":false},"author":1,"featured_media":2607,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NOXXON Supervisory Board elects experienced US &amp; EU Biotech Veteran Don deBethizy Chairman - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NOXXON Supervisory Board elects experienced US &amp; EU Biotech Veteran Don deBethizy Chairman - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"og:description\" content=\"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/\" \/>\n<meta property=\"og:site_name\" content=\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-28T22:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-01-13T15:38:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"norman.krey\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"norman.krey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/\"},\"author\":{\"name\":\"norman.krey\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\"},\"headline\":\"NOXXON Supervisory Board elects experienced US &#038; EU Biotech Veteran Don deBethizy Chairman\",\"datePublished\":\"2017-09-28T22:00:00+00:00\",\"dateModified\":\"2019-01-13T15:38:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/\"},\"wordCount\":579,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"articleSection\":[\"Portfolio News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/\",\"url\":\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/\",\"name\":\"NOXXON Supervisory Board elects experienced US & EU Biotech Veteran Don deBethizy Chairman - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"isPartOf\":{\"@id\":\"https:\/\/dewb.de\/en\/#website\"},\"datePublished\":\"2017-09-28T22:00:00+00:00\",\"dateModified\":\"2019-01-13T15:38:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/dewb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NOXXON Supervisory Board elects experienced US &#038; EU Biotech Veteran Don deBethizy Chairman\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dewb.de\/en\/#website\",\"url\":\"https:\/\/dewb.de\/en\/\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"description\":\"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website\",\"publisher\":{\"@id\":\"https:\/\/dewb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dewb.de\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dewb.de\/en\/#organization\",\"name\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\",\"url\":\"https:\/\/dewb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"contentUrl\":\"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg\",\"width\":300,\"height\":82,\"caption\":\"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG\"},\"image\":{\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b\",\"name\":\"norman.krey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g\",\"caption\":\"norman.krey\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NOXXON Supervisory Board elects experienced US & EU Biotech Veteran Don deBethizy Chairman - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/","og_locale":"en_US","og_type":"article","og_title":"NOXXON Supervisory Board elects experienced US & EU Biotech Veteran Don deBethizy Chairman - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","og_description":"NOXXON publishes preclinical Proof-of-Concept Data for Lead Product NOX-A12 in Combination with Checkpoint Inhibitors","og_url":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/","og_site_name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","article_published_time":"2017-09-28T22:00:00+00:00","article_modified_time":"2019-01-13T15:38:30+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2019\/01\/noxxon.png","type":"image\/png"}],"author":"norman.krey","twitter_card":"summary_large_image","twitter_misc":{"Written by":"norman.krey","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/#article","isPartOf":{"@id":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/"},"author":{"name":"norman.krey","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b"},"headline":"NOXXON Supervisory Board elects experienced US &#038; EU Biotech Veteran Don deBethizy Chairman","datePublished":"2017-09-28T22:00:00+00:00","dateModified":"2019-01-13T15:38:30+00:00","mainEntityOfPage":{"@id":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/"},"wordCount":579,"commentCount":0,"publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"articleSection":["Portfolio News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/","url":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/","name":"NOXXON Supervisory Board elects experienced US & EU Biotech Veteran Don deBethizy Chairman - Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","isPartOf":{"@id":"https:\/\/dewb.de\/en\/#website"},"datePublished":"2017-09-28T22:00:00+00:00","dateModified":"2019-01-13T15:38:30+00:00","breadcrumb":{"@id":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dewb.de\/en\/29-09-17-noxxon-supervisory-board-elects-experienced-us-eu-biotech-veteran-don-debethizy-chairman\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/dewb.de\/en\/"},{"@type":"ListItem","position":2,"name":"NOXXON Supervisory Board elects experienced US &#038; EU Biotech Veteran Don deBethizy Chairman"}]},{"@type":"WebSite","@id":"https:\/\/dewb.de\/en\/#website","url":"https:\/\/dewb.de\/en\/","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","description":"Eine weitere Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG Websites Website","publisher":{"@id":"https:\/\/dewb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dewb.de\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dewb.de\/en\/#organization","name":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG","url":"https:\/\/dewb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","contentUrl":"https:\/\/dewb.de\/en\/wp-content\/uploads\/sites\/2\/2018\/10\/dewb_invers.jpg","width":300,"height":82,"caption":"Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG"},"image":{"@id":"https:\/\/dewb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/cb0cb52ffda9ccee617de58788f6cb2b","name":"norman.krey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dewb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/da8b952883d6ec0b64a529ab8e901992?s=96&d=mm&r=g","caption":"norman.krey"}}]}},"builder_content":"","_links":{"self":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2532"}],"collection":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/comments?post=2532"}],"version-history":[{"count":3,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2532\/revisions"}],"predecessor-version":[{"id":2645,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/posts\/2532\/revisions\/2645"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media\/2607"}],"wp:attachment":[{"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/media?parent=2532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/categories?post=2532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dewb.de\/en\/wp-json\/wp\/v2\/tags?post=2532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}